$Foamix(FOMX)$ 1. Phase I Bridging/Maximal Use (MUSE) trial for FMX101results are expected to be released during Q4 2015; 2. Phase II clinical trial with FDX104, our novel topical foam formulation of doxycycline for the management of acne-like rash in cancer patients taking epidermal growth factor receptor inhibitors (EGFRI) such as Erbitux(R) and Vectibix(R). Results are expected to be released during Q42015. 3. to initiate our Phase III clinical trials for FMX101 in moderate-to-severe acne in early 2016. 机构大量持股（BB, DF等），内部（CEO, COO）持约20%， 与多家大公司合作。